Urintel

This product is user friendly and shall empower clinicians to properly evaluate immunoassay UDT results and guide them in the appropriate direction and actions to take when faced with an unexpected result that yields illicit substances, true and false positives or negatives, and when to quantify results confirmed by definitive gas or liquid chromatography mass spectrometry (GC-MS or LC-MS). Definitive testing is often recommended and implications for missing synthetic cathinones and/or synthetic cannabinoids will be noted as part of the printable (and downloadable) recommendations.

AN EQUAL PLAYING FIELD: A standard practice to interpret these urine screens by immunoassay has been lacking for years, and as such patients and providers have suffered innumerably.

The time has come for individualized patient care, guidance for clinicians (and support for their clinical decisions), and a double check for patients!

This robust tool allows the user to better understand appropriate decision parameters and whether or not the assessment of lab results considers false negatives or positives and drug interactions when evaluating their urine screen results, the purpose of which is to improve communications and encourage patient safety and positive outcomes.

It will help clinicians decipher all the potential permutations and more uniformly arrive at a therapeutic decision. It will help managed care third party payers to uniformly assess logical reasoning for approval and payment for immunoassay and definitive testing by chromatography. This application considers all of these parameters and continued development will incorporate even more individualized patient uniqueness.